WO2015198505A1 - 合成ペンタペプチドの製造法 - Google Patents
合成ペンタペプチドの製造法 Download PDFInfo
- Publication number
- WO2015198505A1 WO2015198505A1 PCT/JP2014/083651 JP2014083651W WO2015198505A1 WO 2015198505 A1 WO2015198505 A1 WO 2015198505A1 JP 2014083651 W JP2014083651 W JP 2014083651W WO 2015198505 A1 WO2015198505 A1 WO 2015198505A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phe
- boc
- added
- lys
- pic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/02—Preparation by ring-closure or hydrogenation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
- C07K1/128—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general sequencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a method for producing a synthetic pentapeptide and its production intermediate.
- ⁇ opioid receptor agonists are known to be useful as therapeutic agents for various pains.
- ⁇ opioid receptor agonists having high selectivity for peripheral ⁇ opioid receptors are expected as pharmaceuticals that do not cause central side effects.
- Synthetic pentapeptides have been reported as such peripherally selective ⁇ opioid receptor agonists (Patent Documents 1 and 2).
- Patent Documents 1 and 2 describe a solid phase peptide synthesis method.
- an object of the present invention is to provide a method for industrially advantageously producing a high purity compound (A).
- the present inventor has studied a method for producing a highly pure compound (A). Surprisingly, only the N-protecting group is eliminated from the N- and O-protected bodies of the compound (A).
- the compound (1) can be purified to a high purity by a slurry method or a recrystallization method. If this is hydrolyzed, a compound (A) having a purity of 90% or more can be obtained. Was found to be industrially advantageous, and the present invention was completed.
- R 1 represents an alkyl group or an aralkyl group
- a salt thereof [2] The compound or salt thereof according to [1], wherein R 1 is an alkyl group. [3] The compound or salt thereof according to [1] or [2], which is an acid addition salt. [4] Formula (A), wherein the compound or salt thereof according to any one of [1] to [3] is hydrolyzed
- the compound (1) can be purified by a simple operation, and if the compound (1) is hydrolyzed, the high-purity compound (A) can be produced industrially advantageously.
- the compound (1) or a salt thereof of the present invention is useful as a synthetic intermediate for the compound (A).
- R 1 represents an alkyl group or an aralkyl group.
- the alkyl group include linear or branched alkyl groups having 1 to 12 carbon atoms. Among these, a linear or branched alkyl group having 1 to 8 carbon atoms is preferable, and a linear or branched alkyl group having 1 to 4 carbon atoms is more preferable.
- the alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, and a tert-butyl group, and a methyl group is particularly preferable.
- an aralkyl group having 7 to 18 carbon atoms is preferable, a C 6-14 aryl-C 1-4 alkyl group is more preferable, a phenyl-C 1-4 alkyl group is more preferable, and a benzyl group is particularly preferable.
- an alkyl group is preferable, a C 1-6 alkyl group is more preferable, a C 1-4 alkyl group is further preferable, and a methyl group is particularly preferable.
- the salt of compound (1) includes acid addition salts, specifically, inorganic acid salts such as hydrochlorides, sulfates and nitrates; organic acid salts such as acetates and trifluoroacetates.
- inorganic acid salt such as hydrochlorides, sulfates and nitrates
- organic acid salts such as acetates and trifluoroacetates.
- hydrochloride is preferable, and as the organic acid salt, trifluoroacetate is preferable. Of these, hydrochloride is more preferable.
- a salt of the compound (1) in which R 1 is a C 1-6 alkyl group is preferable in that it can be easily isolated in a crystalline form and easily purified.
- An acid addition salt of compound (1) wherein 1 is a C 1-6 alkyl group is more preferred, an acid addition salt of compound (1) wherein R 1 is a C 1-4 alkyl group is more preferred, and R 1 is a methyl group
- the acid addition salt of compound (1) is particularly preferred.
- the compound (1) or a salt thereof and the compound (A) are, for example, as shown in the following reaction formula, 4-aminopiperidine-4-carboxylic acid, D-lysine (D-Lys), D-leucine (D-Leu) ), D-phenylalanine (D-Phe) and D-phenylalanine (D-Phe) can be sequentially produced by a liquid phase peptide synthesis method.
- the N-protecting groups represented by P 1 and P 2 are preferably protecting groups that can be removed by different detaching means.
- These protecting groups include (1) protecting groups that can be removed with an acid (for example, tert-butoxycarbonyl group (Boc), p-methoxybenzyloxycarbonyl group (Moz), formyl group (CHO), 2- (trimethylsilyl).
- Ethoxycarbonyl group (Teoc), 1-adamantyloxycarbonyl group (Adoc), 2- (p-biphenyl) isopropyloxycarbonyl group (Bpoc), triphenylmethyl group (Tr), methoxymethyl group (MOM)); 2) Protecting groups that can be removed by reduction (for example, benzyloxycarbonyl group (Cbz), allyl group (Allyl), N-benzyloxymethyl group (BOM)); (3) Protecting groups that can be removed by secondary amines ( For example, 9-fluorenylmethyloxycarbonyl group (Fmoc), 2- (4-nitrophenyl) ethoxycarbonyl group (Npeo) )); (4) Protecting groups that can be eliminated with zinc dust-acetic acid (eg, 2,2,2-trichloroethoxycarbonyl group (Troc), N-dithiasuccinoyl group (Dts), benzothiazole-2- Sulfonyl group (
- Condensation of compound (2) with protected D-Leu, condensation of compound (4) with protected D-Leu, condensation of compound (6) with protected D-Phe, and compound (8) with protected D-Phe For example, molecular sieve, 1-hydroxybenzotriazole (HOBt), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC.HCl), N, N-dicyclohexylcarbodiimide (DCC), etc.
- a condensing agent In the presence of a condensing agent.
- the reaction can be carried out in the presence of a condensing agent in a halogen-based, ester-based or ether-based solvent at 0 to 40 ° C. for 1 to 48 hours.
- the deprotection reaction can be carried out by selecting a method according to the kind of the protecting group.
- a protecting group for example, Boc
- P 1 a protecting group that can be eliminated with an acid
- P 2 a protecting group that can be eliminated by reduction
- Boc is used as P 1
- P 1 if P 1 is deprotected by hydrolysis using an acid, an acid addition salt of compound (1) can be obtained.
- Deprotection by reduction can be carried out, for example, by reaction in an ester-based or ether-based solvent at 0 to 40 ° C. for 1 to 48 hours in the presence of a metal catalyst.
- Deprotection with an acid can be carried out by reaction in an ester or ether solvent in the presence of an inorganic acid or trifluoroacetic acid, for example, at 0 to 40 ° C. for 1 to 48 hours.
- the salt of compound (1) can be easily purified by recrystallization or the like. Further, the salt of compound (1) is sufficiently pure even without purification. Therefore, high purity compound (A) can be produced by hydrolyzing the salt of compound (1).
- the hydrolysis reaction is preferably performed in the presence of a base, for example. Specifically, the reaction can be carried out in the presence of sodium hydroxide or the like in water or an alcohol solvent such as 0 to 40 ° C. for 1 to 48 hours.
- the production method of the compound (A) by the method of the present invention (liquid phase method) it is difficult to produce impurities that are difficult to remove such as diastereomers and defective peptides as compared with the solid phase synthesis method. Can be removed. Further, since the intermediate compound can be isolated as compared with the solid phase synthesis method, it is possible to implement a filtration purification method that is relatively easy to operate and does not require expensive capital investment, such as a slurry method and a recrystallization method. It is easy to obtain a highly pure target product having a purity of 99% by HPLC measurement.
- the solvent to be used is limited, such as methylene chloride and dimethylformamide, but in the liquid phase synthesis method, a safe and inexpensive solvent suitable for industrialization can be used.
- Large-scale synthesis is easier than solid-phase synthesis.
- Solid-phase synthesis often requires “preparative HPLC” (generally expensive equipment and large amounts of organic solvent) to purify the final compound, but liquid-phase synthesis avoids these problems. Can do.
- Example 1 (1) Synthesis of Cbz-D-Lys (Boc) - ⁇ -Boc-Pic-OMe (3) In a 2 L four-necked flask, ⁇ -Boc-Pic-OMe ⁇ HCl [ ⁇ -Boc-4-aminopiperidine -4-Carboxylic acid methyl hydrochloride] (2) 43.7 g (148 mmol) was charged and suspended in 656 mL (15 v / w) of EtOAc.
- the reaction solution was vigorously stirred at room temperature for 18 hours, and after completion of the reaction, Pd / C was removed by filtration under reduced pressure.
- To the obtained filtrate was added NaHCO 3 aq. 441 mL (5.0 v / w) was added for liquid separation, and 200 mL of EtOAc (2.3 v / w) was added to the aqueous layer to extract the organic layer.
- To the combined organic layer was added NaHCO 3 aq. 441 mL (5.0 v / w) was added for liquid separation, and 200 mL of EtOAc (2.3 v / w) was added to the aqueous layer to extract the organic layer. NaClaq. Was added to the combined organic layers.
- the reaction solution was vigorously stirred at room temperature for 8 hours, and after completion of the reaction, vacuum filtration was performed to remove Pd / C.
- To the obtained filtrate was added NaHCO 3 aq. 200 mL (2.2 v / w) was added for liquid separation, and NaHCO 3 aq. 200 mL (2.2 v / w), NaClaq. 200 mL (2.2 v / w) was sequentially added and washed.
- 18.4 g (0.2 w / w) of Na 2 SO 4 was added and dried, and the filtrate obtained by filtration under reduced pressure was concentrated under reduced pressure with an evaporator and pumped up with a vacuum pump.
- Example 2 (Use of trifluoroacetic acid (TFA)) (1) Synthesis of D-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe TFA Salt (1) TFA 18 mL (18 v / w), 1-dodecanethiol 1.6 mL ( 1.6 v / w), 0.2 mL (0.2 v / w) of triisopropylsilane, and 0.2 mL (0.2 v / w) of H 2 O were sequentially added and stirred.
- TFA trifluoroacetic acid
- Example 3 (Using HCl / EtOAc) (1) A 30 mL eggplant flask was charged with 1.00 g (1.01 mmol) of Boc-D-Phe-D-Phe-D-Leu-D-Lys (Boc) - ⁇ -Boc-Pic-OMe (9). 7.0 mL (7.0 v / w) of EtOAc was added and dissolved. 4N HCl / EtOAc (5.0 mL, 5.0 v / w) was added, and the mixture was stirred at room temperature for 24 h. The precipitated solid was filtered off under reduced pressure and filtered, and washed with 2 mL (2.0 v / w) of EtOAc.
- Example 4 Synthesis of compound (A) by hydrolysis of compound (1) (without purification of compound (1))
- a 10 mL eggplant flask was charged with 114.5 mg (0.142 mmol) of D-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe (1) hydrochloride (no purification in the previous step) and 595 ⁇ L of H 2 O. (5.2 v / w) was added and dissolved.
- 586 ⁇ L (0.586 mmol) of 1N NaOH was added dropwise and stirred for 14 h.
- the purity of the obtained compound (A) was less than 80%.
- Example 5 Synthesis of D-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe hydrochloride (1)
- the reaction solvent IPA (1.65 v / w) was replaced with the solvent and amount shown in Table 1. The results are shown in Table 1.
- Example 6 Purification of D-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe Hydrochloride (1)
- the reaction was carried out in the same manner except that the amount of the purified solvent EtOH / MeCN (16.7: 83.5, 20 v / w) was changed to the amount of solvent shown in Table 2. The results are shown in Table 2.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
〔1〕次の式(1)
で表される化合物又はその塩。
〔2〕R1が、アルキル基である〔1〕記載の化合物又はその塩。
〔3〕酸付加塩である〔1〕又は〔2〕記載の化合物又はその塩。
〔4〕〔1〕~〔3〕のいずれかに記載の化合物又はその塩を加水分解することを特徴とする式(A)
固相合成法では、塩化メチレンやジメチルホルムアミド等、使用する溶媒が限定されるのに比べ、液相合成法では、工業化に適した安全で安価な溶媒を使用することが可能である。固相合成法に比べ、大量合成が容易である。固相合成法では最終化合物の精製に「分取HPLC法」(一般的に高額の設備、大量の有機溶媒を要する)を要することが多いが、液相合成法ではこれらの問題を回避することができる。
(1)Cbz-D-Lys(Boc)-α-Boc-Pic-OMe(3)の合成
2Lの4つ口フラスコに、α-Boc-Pic-OMe・HCl[α-Boc-4-アミノピペリジン-4-カルボン酸メチル塩酸塩](2)43.7g(148mmol)を仕込み、EtOAc 656mL(15v/w)に懸濁させた。この懸濁液に1-ヒドロキシベンゾトリアゾール(HOBt)27.2g(178mmol)、Cbz-D-Lys(Boc)-OH 59.2g(156mmol)を加え氷浴にて冷却しながら1-エチル-3-(3-ジメチアミノプロピル)カルボジイミド・HCl(EDC・HCl)34.1g(178mmol)を添加した。20分後、室温に昇温し12時間撹拌した。反応終了後、1N HCl 218mL(5.0v/w)を加え有機層を分液した。得られた有機層にNaHCO3aq.218mL(5.0v/w)、Et3N 33.0g(326mmol)を加え30分撹拌して、分液した。有機層を1N HCl 218mL(5.0v/w)、NaHCO3aq.218mL(5.0v/w)、NaClaq.218mL(5.0v/w)で順次洗浄し、Na2SO4 8.74g(0.2w/w)を加え乾燥させた。減圧濾過を行い、得られた濾液をエバポレーターにて減圧濃縮後、真空ポンプでポンプアップし、Cbz-D-Lys(Boc)-α-Boc-Pic-OMe(3)88.9gを白色固体として得た(収率96.5%、HPLC純度96.5%)。
2Lのナスフラスコに、Cbz-D-Lys(Boc)-α-Boc-Pic-OMe(3)88.3g(142mmol)を仕込み、EtOAcを441mL(5.0v/w)加え溶解させた。反応液に5%Pd/Cを17.7g(0.2w/w)加え、減圧雰囲気下窒素置換を3回行った後、水素置換を3回行った。反応溶液を室温で18時間激しく撹拌し、反応終了後減圧濾過してPd/Cを除去した。得られた濾液にNaHCO3aq.441mL(5.0v/w)を加え分液し、水層にEtOAc 200mL(2.3v/w)を加えて有機層を抽出した。合わせた有機層にNaHCO3aq.441mL(5.0v/w)を加え分液し、水層にEtOAc 200mL(2.3v/w)を加え有機層を抽出した。合わせた有機層にNaClaq.441mL(5.0v/w)を加えて分液し、水層にEtOAc 200mL(2.3v/w)を加えて抽出した。合わせた有機層にNa2SO4 17.7g(0.2w/w)を加え乾燥させ、減圧濾過を行い得た濾液をエバポレーターにて減圧濃縮させ、真空ポンプでポンプアップし、D-Lys(Boc)-α-Boc-Pic-OMe(4)を62.7g得た(収率90.5%、HPLC純度93.6%)。
2Lの4つ口フラスコに、D-Lys(Boc)-α-Boc-Pic-OMe(4)57.7g(120mmol)を仕込み、EtOAc 576mL(10v/w)に懸濁させた。この懸濁液にHOBt 19.3g(126mmol)、Cbz-D-Leu-OH 33.4g(126mmol)を加え氷浴にて冷却しながらEDC・HCl 24.2g(126mmol)を添加した。20分後、室温に昇温し5時間撹拌した後、さらにEDC・HClを1.15g(6.00mmol)添加して16時間撹拌した。反応終了後、1N HCl 576mL(10v/w)を加え分液した。得られた有機層にNaHCO3aq.576mL(10v/w)、Et3N 24.3g(240mmol)を加え30分撹拌して、分液した。有機層を1N HCl 576mL(10v/w)、NaHCO3aq.576mL(10v/w)、NaClaq.576mL(10v/w)で順次洗浄し、Na2SO4 11.5g(0.2w/w)を加え乾燥させた。減圧濾過を行い得られた濾液をエバポレーターにて減圧濃縮後、真空ポンプでポンプアップし、Cbz-D-Leu-D-Lys(Boc)-α-Boc-Pic-OMe(5)85.8gを白色固体として得た(収率98.7%、HPLC純度96.9%)。
1Lのナスフラスコに、Cbz-D-Leu-D-Lys(Boc)-α-Boc-Pic-OMe(5)を91.9g(125mmol)仕込み、EtOAcを459mL(5.0v/w)加え溶解させた。反応液に5%Pd/Cを18.4g(0.2w/w)加え、減圧雰囲気下窒素置換を3回行った後、水素置換を3回行った。反応溶液を室温で8時間激しく撹拌を行い、反応終了後減圧濾過してPd/Cを除去した。得られた濾液にNaHCO3aq.200mL(2.2v/w)を加え分液し、有機層にNaHCO3aq.200mL(2.2v/w)、NaClaq.200mL(2.2v/w)を順次加え洗浄した。得られた有機層にNa2SO4 18.4g(0.2w/w)を加え乾燥させ、減圧濾過を行い得た濾液をエバポレーターにて減圧濃縮させ、真空ポンプでポンプアップした。得られたアモルファス状の固体にEtOAc 200mL(2.2v/w)を加え溶解させ、ヘプタン50mL(1.8v/w)を加えて晶析させた。減圧濾過して析出結晶を濾別し、EtOAc 120mL(1.3v/w)、ヘプタン50mL(0.3v/w)の混合溶媒で結晶を洗浄した。得られた結晶46.1gにEtOAc 480mL(5.2v/w)を加え溶解させ、シクロヘキサン660mL(7.2v/w)を加え晶析させた。減圧濾過して析出結晶を濾別し、シクロヘキサン120mL(1.3v/w)、EtOAc 20mL(0.2v/w)の混合溶媒で洗浄し、30℃減圧乾燥し、白色固体としてD-Leu-D-Lys(Boc)-α-Boc-Pic-OMe(6)を36.6g得た(収率48.7%、HPLC純度99.9%)。
1Lの4つ口フラスコに、D-Leu-D-Lys(Boc)-α-Boc-Pic-OMe(6)を35.8g(59.6mmol)仕込み、EtOAc 358mL(10v/w)に懸濁させた。この懸濁液にHOBt 9.59g(62.6mmol)、Cbz-D-Phe-OH 18.7g(62.6mmol)を加え氷浴にて冷却しながらEDC・HCl 12.0g(62.6mmol)を添加した。20分後、室温に昇温し16時間撹拌した後さらにEDC・HClを3.09g(16.1mmol)添加した。反応終了後、1N HCl 358mL(10v/w)を加え有機層を分液した。得られた有機層にNaHCO3aq.358mL(10v/w)、Et3N 12.1g(119mmol)を加え30分撹拌して、分液した。有機層を1N HCl 358mL(10v/w)、NaHCO3aq.358mL(10v/w)、NaClaq.358mL(10v/w)で順次洗浄し、Na2SO4 7.16g(0.2w/w)を加え乾燥させた。減圧濾過を行い得た濾液をエバポレーターにて減圧濃縮後、真空ポンプでポンプアップし、Cbz-D-Phe-D-Leu-D-Lys(Boc)-α-Boc-Pic-OMe(7)を白色固体として52.5g得た(収率quant、HPLC純度97.6%)。
2Lのナスフラスコに、Cbz-D-Phe-D-Leu-D-Lys(Boc)-α-Boc-Pic-OMe(7)を46.9g(53.3mmol)仕込み、EtOAcを840mL(18v/w)、H2O 93.8mL(2.0v/w)を加え溶解させた。反応液に5% Pd/Cを9.38g(0.2w/w)加え、減圧雰囲気下窒素置換を3回行った後、水素置換を3回行った。反応溶液を室温で10時間激しく撹拌を行い、反応終了後減圧濾過してPd/Cを除去した。得られた濾液にNaHCO3aq.235mL(5.0v/w)を加え分液し、有機層にNaHCO3aq.235mL(5.0v/w)、NaClaq.235mL(5.0v/w)を順次加え洗浄した。得られた有機層にNa2SO4 9.38g(0.2w/w)を加え乾燥させ、減圧濾過を行い得た濾液をエバポレーターにて減圧濃縮させ、真空ポンプでポンプアップしてD-Phe-D-Leu-D-Lys(Boc)-α-Boc-Pic-OMe(7)を39.7g得た(収率quant、HPLC純度97.3%)。
1Lの4つ口フラスコに、D-Phe-D-Leu-D-Lys(Boc)-α-Boc-Pic-OMe(8)を35.1g仕込み、EtOAc 351mL(10v/w)に懸濁させた。この懸濁液にHOBt 7.92g(51.7mmol)、Boc-D-Phe-OH 13.1g(49.4mmol)を加え氷浴にて冷却しながらEDC・HCl 9.91g(51.7mmol)を添加した。20分後、室温に昇温し8時間撹拌後さらにEDC・HClを2.25g(11.7mmol)添加した。反応終了後、1N HCl 351mL(10v/w)を加え有機層を分液した。得られた有機層にNaHCO3aq.351mL(10v/w)、Et3N 9.51g(94.0mmol)を加え30分撹拌して、分液した。有機層を1N HCl 351mL(10v/w)、NaHCO3aq.351mL(10v/w)、NaClaq.351mL(10v/w)で順次洗浄し、Na2SO4 7.02g(0.2w/w)を加え乾燥させた。減圧濾過を行い得た濾液をエバポレーターにて減圧濃縮後、真空ポンプでポンプアップし、Boc-D-Phe-D-Phe-D-Leu-D-Lys(Boc)-α-Boc-Pic-OMe(9)を白色固体として46.7g得た(収率quant、HPLC純度98.6%)。
20mLのナスフラスコにBoc-D-Phe-D-Phe-D-Leu-D-Lys(Boc)-α-Boc-Pic-OMe(9)を2.00g仕込み、IPA 3.3mL(1.65v/w)、PhMe 10mL(5v/w)を加えて懸濁させた。6N HCl/IPA 6.7mL(3.35v/w)を加えて室温で19時間撹拌した。析出した固体を減圧濾過で濾別し、減圧乾燥して白色固体のD-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe塩酸塩(1)を1.59g(収率99.0%、HPLC純度98.2%)得た。
20mLのナスフラスコにD-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe塩酸塩粗晶(1)200mgを仕込み、EtOH:MeCN=1:5の混合溶媒4.0mL(20v/w)を加え40℃に加熱して1時間撹拌した後、さらに室温で2時間撹拌スラリーした。減圧濾過して濾別し、得られた固体を減圧乾燥して白色固体((1)精製晶)を161mg得た(収率80%、HPLC純度99.2%)。
10mLのナスフラスコにD-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe塩酸塩(1)精製晶38.5mg(0.0488mmol)を仕込み、H2O 0.2mL(5.2v/w)を加え溶解させた。室温にて1N NaOH 197μL(0.197mmol)を滴下して1.5h撹拌した。反応終了後、1N HCl 48.8μL(0.0488mmol)を加えエバポレーターにて減圧濃縮を行い、D-Phe-D-Phe-D-Leu-D-Lys-Pic(A)を得た(収率quant、HPLC純度99.7%)。
1H NMR(400MHz, 1M DCl) δ ppm : 0.85-1.02 (m, 6 H), 1.34-1.63 (m, 5 H), 1.65-2.12 (m, 5 H), 2.23-2.45 (m, 2 H), 2.96-3.12 (m, 4 H), 3.19 (ddt, J = 5.0 & 5.0 & 10.0 Hz), 3.33-3.62 (m, 1 H), 3.68-3.82 (m, 1 H), 3.82-3.95 (m, 4 H), 3.95-4.18 (m, 1 H), 4.25-4.37 (m, 2 H), 4.61-4.77 (m, 2 H), 7.21-7.44 (m, 10 H)
13C NMR(400MHz, 1M DCl) δ ppm : 21.8, 22.5, 24.8, 27.0, 30.5, 30.8, 31.0, 31.2, 31.7, 37.2, 37.8, 38.4, 39.0, 39.8, 40.4, 40.6, 41.8, 42.3, 49.8, 50.2, 52.2, 52.6, 54.6, 55.2, 57.7, 57.9, 127.6, 128.4, 129.2, 129.6, 129.7, 129.8
d.p 209.5℃
(トリフルオロ酢酸(TFA)使用)
(1)D-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe TFA塩(1)の合成
50mLのナスフラスコにTFA 18mL(18v/w)、1-ドデカンチオール1.6mL(1.6v/w)、トリイソプロピルシラン0.2mL(0.2v/w)、H2O 0.2mL(0.2v/w)を順次加え撹拌した。その溶液にBoc-D-Phe-D-Phe-D-Leu-D-Lys(Boc)-α-Boc-Pic-OMe(9)1.00g(1.01mmol)をスパチュラで少量ずつ添加した。反応終了後、エバポレーターにて減圧濃縮を行い、得られた残渣をIPE 20mL(20v/w)に滴下した。析出した固体を濾別し、得られた固体を減圧乾燥して白色固体としてD-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe・TFA塩(1)を得た(収率93.0%、HPLC純度95.2%)。
10mLのナスフラスコにD-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe TFA塩(1)83mg(0.0843mmol)を仕込み、H2O 431μL(5.2v/w)を加えて溶解させた。室温にて1N NaOH 345μL(0.345mmol)を滴下して12h撹拌した。反応終了後、1N HCl 84.3μL(0.0843mmol)を加えエバポレーターにて減圧濃縮を行い、D-Phe-D-Phe-D-Leu-D-Lys-Pic(A)を得た(収率quant、HPLC純度95.4%)。
(HCl/EtOAc使用)
(1)30mLのナスフラスコにBoc-D-Phe-D-Phe-D-Leu-D-Lys(Boc)-α-Boc-Pic-OMe(9)1.00g(1.01mmol)を仕込み、EtOAc7.0mL(7.0v/w)を加え溶解させた。4N HCl/EtOAc 5.0mL(5.0v/w)を加え室温で24h撹拌後、析出した固体を減圧濾過して濾別し、EtOAc 2mL(2.0v/w)で洗浄した。得られた固体を減圧乾燥して白色固体としてD-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe 塩酸塩(1)を781mg得た(収率96.7%、HPLC純度95.4%)。
10mLのナスフラスコにD-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe 塩酸塩(1)90mg(0.112mmol)を仕込み、H2O 0.47mL(5.2v/w)を加えて溶解させた。室温にて1N NaOH 459μL(0.459mmol)を滴下して12h撹拌した。反応終了後、1N HCl 0.112μL(0.112mmol)を加えエバポレーターにて減圧濃縮を行い、D-Phe-D-Phe-D-Leu-D-Lys-Pic(A)を得た(収率quant、HPLC純度93.1%)。
化合物(1)の加水分解による化合物(A)の合成(化合物(1)の精製なし)
10mLのナスフラスコにD-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe(1)塩酸塩(前工程精製なし)114.5mg(0.142mmol)を仕込み、H2O 595μL(5.2v/w)を加え溶解させた。室温にて1N NaOH 586μL(0.586mmol)を滴下して14h撹拌した。反応終了後、1N HCl 0.15μL(0.150mmol)を加えエバポレーターにて減圧濃縮を行い、D-Phe-D-Phe-D-Leu-D-Lys-Pic(A)を得た(収率quant、HPLC純度95.2%)。
化合物(1)を経由しない経路(全保護体Boc-D-Phe-D-Phe-D-Leu-D-Lys(Boc)-α-Boc-Pic-OMe(a)を使用)
(1)Boc-D-Phe-D-Phe-D-Leu-D-Lys(Boc)-α-Boc-Pic-OHの合成
30mLのナスフラスコにBoc-D-Phe-D-Phe-D-Leu-D-Lys(Boc)-α-Boc-Pic-OMe(9)1.00g(1.00mmol)を仕込み、MeOH 5.0mL(5.0v/w)を加えて溶解させた。室温にて1N NaOH 1.1mL(1.10mmol)を加えて4日間撹拌後、さらにMeOH 5.0mL(5.0v/w)、1N NaOH 2.0mL(2.0mmol)を加えて35℃で3h撹拌した。反応終了後1N HCl 6.1mLを加え、減圧濃縮して溶媒を留去した後、EtOAc 5.0mL(5.0mL)を加えて有機層を分液した。NaClaq.5.0mL(5.0v/w)を加えて有機層を洗浄し、有機層を減圧濃縮して白色固体としてBoc-D-Phe-D-Phe-D-Leu-D-Lys(Boc)-α-Boc-Pic-OH 975.1mg(収率99.3%、HPLC純度80.8%)
20mLのナスフラスコにBoc-D-Phe-D-Phe-D-Leu-D-Lys(Boc)-α-Boc-Pic-OH(10)959mg(0.978mmol)を仕込み、EtOAc 4.9mL(5.0v/w)を加えて溶解させた。室温にて4N HCl/EtOAc 4.9mL(5.0mL)を滴下して室温にて4h撹拌した。反応終了後、減圧濾過して、白色固体としてD-Phe-D-Phe-D-Leu-D-Lys-Pic(A)を得た(収率96.4%、HPLC純度79.2%)。
(D-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe塩酸塩(1)の合成)
前記実施例1の(8)において、反応溶媒IPA(1.65v/w)を、表1の溶媒と量に代えて同様に反応を行った。結果を表1に示す。
(D-Phe-D-Phe-D-Leu-D-Lys-Pic-OMe塩酸塩(1)の精製)
前記実施例1の(9)において、精製溶媒EtOH/MeCN(16.7:83.5、20v/w)を、表2の溶媒と量に代えて同様に反応を行った。結果を表2に示す。
Claims (4)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14896077.6A EP3162810B1 (en) | 2014-06-26 | 2014-12-19 | Method for producing synthetic pentapeptide |
RU2017102307A RU2664545C2 (ru) | 2014-06-26 | 2014-12-19 | Способ получения синтетического пентапептида |
CA2953653A CA2953653C (en) | 2014-06-26 | 2014-12-19 | Method for producing synthetic pentapeptide |
KR1020167035817A KR102303092B1 (ko) | 2014-06-26 | 2014-12-19 | 합성 펜타펩티드의 제조법 |
JP2015524274A JP5807140B1 (ja) | 2014-06-26 | 2014-12-19 | 合成ペンタペプチドの製造法 |
MX2016016479A MX2016016479A (es) | 2014-06-26 | 2014-12-19 | Metodo para producir un pentapeptido sintetico. |
CN201480080015.1A CN106459150B (zh) | 2014-06-26 | 2014-12-19 | 合成五肽的制造方法 |
US15/320,488 US10035767B2 (en) | 2014-06-26 | 2014-12-19 | Method for producing synthetic pentapeptide |
AU2014398345A AU2014398345B2 (en) | 2014-06-26 | 2014-12-19 | Method for producing synthetic pentapeptide |
ES14896077T ES2715082T3 (es) | 2014-06-26 | 2014-12-19 | Método de producción de un pentapéptido sintético |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-130891 | 2014-06-26 | ||
JP2014130891 | 2014-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015198505A1 true WO2015198505A1 (ja) | 2015-12-30 |
Family
ID=54937619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/083651 WO2015198505A1 (ja) | 2014-06-26 | 2014-12-19 | 合成ペンタペプチドの製造法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US10035767B2 (ja) |
EP (1) | EP3162810B1 (ja) |
KR (1) | KR102303092B1 (ja) |
CN (1) | CN106459150B (ja) |
AU (1) | AU2014398345B2 (ja) |
CA (1) | CA2953653C (ja) |
ES (1) | ES2715082T3 (ja) |
MX (1) | MX2016016479A (ja) |
RU (1) | RU2664545C2 (ja) |
SA (1) | SA516380521B1 (ja) |
TR (1) | TR201902611T4 (ja) |
WO (1) | WO2015198505A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109563133B (zh) | 2016-09-27 | 2020-09-11 | 四川科伦博泰生物医药股份有限公司 | 多酰胺化合物及其用途 |
BR112020011191A2 (pt) * | 2017-12-06 | 2020-11-17 | Jiangsu Hengrui Medicine Co., Ltd. | sal de derivado de fenilpropionamida, métodos para preparar o mesmo, bem como sua composição farmacêutica e uso dos mesmos |
WO2019154151A1 (zh) * | 2018-02-12 | 2019-08-15 | 四川科伦博泰生物医药股份有限公司 | 一种中间体化合物及其制备方法,及以该中间体化合物制备多肽的固相合成方法 |
AU2020454871A1 (en) | 2020-06-25 | 2023-01-19 | Humanwell Pharmaceutical US | Peptides for treatment of medical disorders |
WO2024015106A1 (en) * | 2022-07-11 | 2024-01-18 | Humanwell Pharmacuetical Us | Peptides for treatment of medical disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010510966A (ja) * | 2006-11-10 | 2010-04-08 | カラ セラピューティクス インコーポレイテッド | 合成ペプチドアミドおよびその二量体 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965701A (en) * | 1997-12-23 | 1999-10-12 | Ferring Bv | Kappa receptor opioid peptides |
US8236766B2 (en) * | 2006-11-10 | 2012-08-07 | Cara Therapeutics, Inc. | Uses of synthetic peptide amides |
MY148144A (en) | 2006-11-10 | 2013-03-15 | Cara Therapeutics Inc | Synthetic peptide amides |
US8906859B2 (en) * | 2006-11-10 | 2014-12-09 | Cera Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
US7713937B2 (en) | 2006-11-10 | 2010-05-11 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
JP2010539183A (ja) * | 2007-09-12 | 2010-12-16 | ドクター・レディーズ・ラボラトリーズ・リミテッド | ボルテゾミブおよびその生成のためのプロセス |
CN102924569A (zh) * | 2012-09-14 | 2013-02-13 | 烟台海安多肽药物研发技术有限公司 | 一种依替巴肽的液相合成方法 |
-
2014
- 2014-12-19 US US15/320,488 patent/US10035767B2/en not_active Expired - Fee Related
- 2014-12-19 AU AU2014398345A patent/AU2014398345B2/en not_active Ceased
- 2014-12-19 CN CN201480080015.1A patent/CN106459150B/zh not_active Expired - Fee Related
- 2014-12-19 MX MX2016016479A patent/MX2016016479A/es active IP Right Grant
- 2014-12-19 WO PCT/JP2014/083651 patent/WO2015198505A1/ja active Application Filing
- 2014-12-19 KR KR1020167035817A patent/KR102303092B1/ko active IP Right Grant
- 2014-12-19 CA CA2953653A patent/CA2953653C/en not_active Expired - Fee Related
- 2014-12-19 ES ES14896077T patent/ES2715082T3/es active Active
- 2014-12-19 RU RU2017102307A patent/RU2664545C2/ru active
- 2014-12-19 EP EP14896077.6A patent/EP3162810B1/en active Active
- 2014-12-19 TR TR2019/02611T patent/TR201902611T4/tr unknown
-
2016
- 2016-12-19 SA SA516380521A patent/SA516380521B1/ar unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010510966A (ja) * | 2006-11-10 | 2010-04-08 | カラ セラピューティクス インコーポレイテッド | 合成ペプチドアミドおよびその二量体 |
Non-Patent Citations (4)
Title |
---|
ALBERICIO, F.: "Orthogonal Protecting Groups for Nalpha-Amino and C-Terminal Carboxyl Functions in Solid-Phase Peptide Synthesis", BIOPOLYMERS (PEPTIDE SCIENCE, vol. 55, no. 2, 2000, pages 123 - 139, XP009104378, ISSN: 0006-3525 * |
See also references of EP3162810A4 * |
SHUNPEI SAKAKIBARA: "Tanpakushitsu no Kagaku Gosei", PROTEIN, NUCLEIC ACID AND ENZYME, vol. 40, no. 3, 1995, pages 304 - 316, XP008184143 * |
TAKAHASHI, D. ET AL.: "Novel diphenylmethyl- Derived Amide Protecting Group for Efficient Liquid-Phase Peptide Synthesis: AJIPHASE", ORGANIC LETTERS, vol. 14, no. 17, 2012, pages 4514 - 4517, XP055246787, ISSN: 1523-7060 * |
Also Published As
Publication number | Publication date |
---|---|
CN106459150B (zh) | 2020-01-24 |
EP3162810A1 (en) | 2017-05-03 |
US20170183307A1 (en) | 2017-06-29 |
TR201902611T4 (tr) | 2019-03-21 |
SA516380521B1 (ar) | 2020-04-26 |
CA2953653C (en) | 2021-02-16 |
RU2017102307A (ru) | 2018-07-26 |
AU2014398345A1 (en) | 2017-02-16 |
RU2664545C2 (ru) | 2018-08-20 |
CA2953653A1 (en) | 2015-12-30 |
MX2016016479A (es) | 2017-04-10 |
KR102303092B1 (ko) | 2021-09-15 |
RU2017102307A3 (ja) | 2018-07-26 |
US10035767B2 (en) | 2018-07-31 |
EP3162810A4 (en) | 2018-01-24 |
EP3162810B1 (en) | 2019-02-13 |
AU2014398345B2 (en) | 2019-01-17 |
KR20170020808A (ko) | 2017-02-24 |
ES2715082T3 (es) | 2019-05-31 |
CN106459150A (zh) | 2017-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6162795B2 (ja) | リシン−グルタミン酸ジペプチド誘導体 | |
US11952341B2 (en) | Method of preparing high chiral purity lactam intermediate and brivaracetam | |
JPWO2019198833A1 (ja) | ペプチド合成方法 | |
WO2015198505A1 (ja) | 合成ペンタペプチドの製造法 | |
CN107474107B (zh) | Glyx-13的制备方法及用于制备glyx-13的化合物 | |
JP6703669B2 (ja) | リュープロレリンの製造方法 | |
Chung et al. | Cyclic peptide facial amphiphile preprogrammed to self-assemble into bioactive peptide capsules | |
EP4251632A1 (en) | Compositions and methods for chemical synthesis | |
JP5807140B1 (ja) | 合成ペンタペプチドの製造法 | |
KR20220059479A (ko) | 트로피네타이드의 조성물 | |
WO2013131978A1 (en) | Process for the preparation of intermediates useful in the preparation of a viral protease inhibitor | |
JP7278775B2 (ja) | 長鎖化合物の製造方法 | |
Mansour | Dipeptide Analogues: Synthesis of C-Terminal p-Nitrobenzyl-3-ketoesters of N-Protected Amino Acids | |
WO2013057736A2 (en) | Preparation of eptifibatide peptide | |
CN113024637B (zh) | 一种以水溶性炔酰胺作为缩合剂制备卡非佐米的方法 | |
WO2013044714A1 (zh) | D-异谷氨酰基-d-色氨酸制备的新方法 | |
JP5397706B2 (ja) | 高純度1−ベンジル−3−アミノピロリジンの製造方法 | |
JP2016065050A (ja) | オクトレオチドの製造法 | |
JP5982720B2 (ja) | 高分子固体状支持体を用いたヒスチジル−プロリンアミド誘導体の製造方法 | |
JP2016013977A (ja) | trans−1,2−ジアミノシクロヘキサンの製造方法 | |
CN102146065A (zh) | 一种高纯度二酮哌嗪环肽的制备方法 | |
JP2001031635A (ja) | 光学活性n−保護−n−メチル−フェニルアラニン誘導体の製造方法 | |
KR20200082987A (ko) | 탈티렐린 및 이의 중간체의 신규한 제조방법 | |
JP2006528168A (ja) | インテグリン阻害剤として有用な、rgd配列を含有するペプチド様化合物及びその中間体 | |
JP2009263272A (ja) | ヘテロ元素を有する脂環式アミノ酸誘導体およびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2015524274 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14896077 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2014896077 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/016479 Country of ref document: MX Ref document number: 2014896077 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15320488 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20167035817 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2953653 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016030563 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2017102307 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014398345 Country of ref document: AU Date of ref document: 20141219 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112016030563 Country of ref document: BR Kind code of ref document: A2 Effective date: 20161226 |